Enliven Therapeutics (ELVN) Projected to Post Quarterly Earnings on Thursday

Enliven Therapeutics (NASDAQ:ELVN) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN opened at $21.25 on Thursday. Enliven Therapeutics has a 1 year low of $10.90 and a 1 year high of $30.03. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -11.18 and a beta of 1.04. The stock’s 50-day simple moving average is $21.89 and its 200-day simple moving average is $23.92.

Wall Street Analyst Weigh In

ELVN has been the topic of a number of analyst reports. BTIG Research initiated coverage on Enliven Therapeutics in a research report on Friday, December 13th. They set a “buy” rating and a $42.00 target price on the stock. Robert W. Baird lifted their target price on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $38.25.

Insider Activity at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $25.04, for a total transaction of $25,040.00. Following the completion of the transaction, the chief financial officer now directly owns 13,000 shares of the company’s stock, valued at approximately $325,520. This represents a 7.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Anish Patel sold 6,667 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $21.93, for a total value of $146,207.31. Following the transaction, the chief operating officer now directly owns 329,977 shares of the company’s stock, valued at $7,236,395.61. This trade represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 41,117 shares of company stock valued at $949,435 over the last three months. 29.20% of the stock is owned by insiders.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.